Heparin Sodium

Introduction Overview

Generic Name

Heparin Sodium

Brand Name

HepFlush

Dosage Form

Parenteral injection and lock flush solutions

Drug Class

Heparins (Unfractionated heparin)

Pharmacokinetics

Absorption:
Heparin sodium exhibits distinct absorption characteristics depending on the route of administration. Upon subcutaneous administration, peak plasma concentrations are typically achieved within 2 to 4 hours, reflecting its moderate systemic absorption. The onset of anticoagulant action following subcutaneous injection occurs within 20 to 60 minutes, while intravenous (IV) administration results in an immediate onset of action due to direct systemic delivery. Heparin lock flush solutions maintain anticoagulant activity within catheters for approximately 4 hours. Clinical and pharmacokinetic studies have demonstrated increased plasma heparin concentrations and prolonged activated partial thromboplastin times (aPTT) in geriatric patients (>60 years), suggesting altered absorption or metabolism in this population.

Distribution:
Heparin sodium is extensively bound to plasma proteins including low-density lipoproteins (LDL), globulins, and fibrinogen, which influences both its pharmacokinetics and pharmacodynamics. This extensive binding partially accounts for the observed disparity between plasma concentration half-life and duration of anticoagulant effect. Importantly, heparin does not cross the placental barrier and is not secreted into breast milk, which informs its safety profile during pregnancy and lactation. Distribution volume studies indicate confinement primarily to the vascular compartment due to its high molecular weight and polarity.

Metabolism:
The metabolism of heparin occurs predominantly via the reticuloendothelial system, where it undergoes enzymatic cleavage and fragmentation. Additionally, partial hepatic metabolism to uroheparin, a desulfated heparin derivative, has been documented. Metabolic clearance is subject to saturation, which contributes to nonlinear pharmacokinetics at higher doses. Liver impairment leads to decreased plasma half-life of heparin, possibly due to altered metabolic capacity or protein binding.

Elimination:
Heparin elimination is biphasic with plasma half-life varying according to dosage. In healthy adults, half-life ranges from approximately 56 minutes at 100 units/kg to 152 minutes at 400 units/kg administered intravenously, illustrating dose-dependent prolongation. Renal clearance accounts for a minor fraction, with unchanged drug excreted in urine. Patients with severe renal impairment or anephric status may experience slight prolongation of heparin half-life. Notably, patients with pulmonary embolism tend to exhibit shorter half-lives compared to healthy subjects. Hepatic cirrhosis may prolong elimination half-life, underscoring the need for careful monitoring in hepatic dysfunction.

Dosage Forms

Available Dosage Forms:
Heparin sodium is available exclusively as a parenteral agent due to its physicochemical properties and absorption limitations.
- Injection (extracted from porcine intestinal mucosa) with concentrations of 1000 units/mL, 5000 units/mL, 10,000 units/mL, and 20,000 units/mL.
- Heparin lock flush solutions designed for catheter maintenance, available at 10 units/mL (in volumes delivering 10, 20, 30, 50, 100, 300 units) and 100 units/mL (in volumes delivering 100, 200, 300, 500, 1000, 3000 units).
- Preservative-free injections formulated with dextrose or sodium chloride at various concentrations (e.g., 40 units/mL [20,000 units per vial], 50 units/mL [12,500 or 25,000 units], 100 units/mL [10,000 or 25,000 units]).
- Solutions designed for IV infusion in 5% dextrose or 0.9%/0.45% sodium chloride to facilitate continuous infusion.

Dosages for Adults and Adolescents:
- Treatment of deep vein thrombosis (DVT) and pulmonary embolism (PE) includes an initial IV bolus of 5000-10,000 units, followed by subcutaneous or continuous IV administration of 8000–20,000 units every 8–12 hours, or continuous IV infusion of 20,000–40,000 units over 24 hours depending on institutional protocols.
- Prophylaxis in general surgery involves 5000 units subcutaneously 2 hours before surgery and every 8–12 hours postoperatively for 7 days or until the patient is ambulatory.
- Dosage adjustment for specific indications such as acute coronary syndromes, cardiopulmonary bypass, or catheter-related thrombosis is individualized and guided by coagulation parameters.

Specific Patient Populations:
- Pediatric: Lack of robust clinical trials necessitates dose individualization. Loading doses of 75–100 units/kg IV over 10 minutes followed by continuous infusion of 18–30 units/kg/hour are used, targeting anti-factor Xa levels of 0.35–0.7 units/mL or corresponding aPTT values. Lower maintenance dosing is employed in neonates and infants due to age-dependent clearance differences.
- Geriatric patients (>60 years) often require lower dosages due to increased bleeding risk and altered pharmacokinetics.
- Pregnancy: Subcutaneous dosing tailored to maintain aPTT or anti-factor Xa levels generally in the range of 17,500–20,000 units every 12 hours for women with mechanical heart valves, with adjustments based on trimester and coagulation monitoring.
- Renal impairment: While elimination is not primarily renal, cautious dosing and monitoring are advised given potential for prolonged half-life and bleeding risk.

Administration guidance notes avoidance of intramuscular injection due to bleeding risk, preference for deep subcutaneous injection using fine gauge needles, and caution to differentiate between heparin formulations to prevent medication errors.

Mechanism Of Action

Heparin sodium functions as an anticoagulant by catalyzing the action of antithrombin III (ATIII), a naturally occurring serine protease inhibitor. This interaction markedly accelerates the neutralization of activated coagulation factors, particularly thrombin (factor IIa) and activated factor X (factor Xa), thereby inhibiting the formation of fibrin clots. At low doses, heparin predominantly enhances ATIII-mediated inhibition of factor Xa, preventing the generation of thrombin and thereby limiting fibrin synthesis. This selective inhibition helps prevent thrombus formation without significantly affecting existing clots.

At higher therapeutic doses, heparin binds to ATIII and thrombin simultaneously, forming a ternary complex that accelerates the inactivation of thrombin itself. This action prevents the conversion of fibrinogen to fibrin and inhibits activation of fibrin-stabilizing factor (factor XIII), resulting in impediment of clot consolidation and extension. Full-dose heparin disrupts platelet aggregation and reduces fibrin network stability, thus mitigating thrombus propagation.

Heparin's anticoagulant effects manifest in prolongation of multiple coagulation assays including activated clotting time (ACT), activated partial thromboplastin time (aPTT), plasma recalcification time, and thrombin time. These laboratory parameters guide dosing adjustments in clinical practice to maintain therapeutic anticoagulation while minimizing bleeding risk.

Compared to low molecular weight heparins (LMWHs) and synthetic pentasaccharides, unfractionated heparin has a broader spectrum of activity, neutralizing multiple coagulation factors and possessing a shorter half-life with reversible effects using protamine sulfate. These properties allow for precise titration in complex clinical scenarios, such as cardiac surgery or extracorporeal circulation. Numerous clinical studies have demonstrated the efficacy of heparin in venous thromboembolism prophylaxis, acute coronary syndromes, and extracorporeal therapies, supporting its continued role as a critical anticoagulant despite the availability of newer agents.

Pharmacological Actions

Accelerates antithrombin III-mediated inactivation of thrombin (factor IIa) and factor Xa.
Prevents conversion of fibrinogen to fibrin, inhibiting clot formation.
Blocks activation of fibrin-stabilizing factor (factor XIII), disrupting clot stabilization.
Prolongs multiple coagulation assays including aPTT, ACT, and thrombin time.
Exerts antithrombotic effects by inhibiting thrombus formation and propagation.
Neutralizes various activated coagulation factors beyond thrombin and factor Xa.
Has a rapid onset of action when administered intravenously.
Does not cross the placenta or enter breast milk, limiting fetal exposure.
Interferes with platelet function and reduces platelet aggregation.
Short plasma half-life allows for rapid titration and reversal.
Can be neutralized effectively by protamine sulfate in cases of overdose or bleeding.
Binds extensively to plasma proteins affecting its pharmacodynamics.
Used intravenously and subcutaneously but not orally due to poor absorption.
Possesses anti-inflammatory properties through interaction with various plasma proteins.
Exhibits dose-dependent anticoagulant activity.

Therapeutic Or Clinical Uses

Treatment of acute and chronic venous thromboembolism, including deep vein thrombosis and pulmonary embolism.
Prophylaxis of postoperative deep vein thrombosis and pulmonary embolism in general surgery patients at risk.
Thromboprophylaxis in cardiac surgery patients, particularly those with complicated postoperative courses.
Prevention of venous thromboembolism in neurosurgical and spinal surgery patients at very high risk, in combination with mechanical methods.
Prophylaxis in major orthopedic surgeries, including total hip and knee replacement and hip fracture surgeries.
Anticoagulation in acutely ill hospitalized medical patients with high risk of thromboembolism.
Thromboprophylaxis in trauma patients at risk for venous thromboembolism.
Prevention and treatment of thromboembolism during pregnancy, notably in women with mechanical heart valves or antiphospholipid syndrome.
Treatment and secondary prevention of venous thromboembolism in pediatric patients, including neonates.
Reduction of thromboembolic risk during electrical or pharmacologic cardioversion for atrial fibrillation or flutter.
Bridging anticoagulation therapy in patients with prosthetic mechanical heart valves transitioning to warfarin.
Treatment of disseminated intravascular coagulation and other consumptive coagulopathies.
Maintenance of patency of indwelling venous or arterial catheters via heparin flush solutions.
Adjunct therapy in ST-segment elevation myocardial infarction (STEMI) during thrombolytic therapy.
Anticoagulation during percutaneous coronary interventions to prevent thrombotic complications.
Management of non-ST-segment elevation acute coronary syndromes (NSTE ACS).
Treatment of cerebral venous sinus thrombosis and acute ischemic stroke in selected patients.
Use in extracorporeal circulation, dialysis, and blood sample anticoagulation.

Side Or Adverse Effects

Bleeding complications ranging from minor ecchymoses to life-threatening hemorrhage.
Heparin-induced thrombocytopenia (HIT) with or without thrombosis, a serious immune-mediated adverse effect.
Local injection site reactions including pain, irritation, and hematoma formation.
General hypersensitivity reactions such as rash, fever, and anaphylaxis in rare cases.
Elevation of aminotransferase (ALT and AST) levels during therapy.
Osteoporosis with long-term use, especially in patients receiving prolonged high doses.
Thrombocytopenia may be mild and reversible, but close monitoring is essential.
Potential for hyperkalemia through suppression of aldosterone synthesis.
Alopecia reported with prolonged therapy.
Heparin resistance in certain clinical conditions, requiring higher doses for therapeutic effect.
Rare occurrence of skin necrosis and gangrene associated with HIT.
Allergic reactions related to sensitivity to pork-derived products in susceptible individuals.
Potential contamination or overdose risks due to medication errors with different formulations.
Possible exacerbation of underlying coagulopathies if not monitored properly.
Risk of epidural or spinal hematomas when used in conjunction with neuraxial anesthesia.

Precautions

Use with caution in patients with increased risk of bleeding due to surgery, trauma, or comorbidities.
Monitor coagulation parameters (aPTT, ACT) regularly, especially in full-dose therapy.
Avoid intramuscular administration due to risk of hematoma.
Screen patients for bleeding disorders prior to initiating therapy.
Closely observe platelet counts to detect early signs of HIT.
Adjust doses in geriatric patients to minimize hemorrhagic risk.
Use preservative-free formulations in neonates, infants, pregnant and nursing women to avoid benzyl alcohol toxicity.
Discontinue heparin immediately if severe bleeding or clinically important thrombocytopenia occurs.
Be vigilant during perioperative management, especially regarding timing of discontinuation and resumption relative to surgery.
Cautious administration in patients with severe hepatic or renal impairment.
Accurately distinguish between different heparin products to prevent medication errors.
Consider lower doses or alternative anticoagulants in patients with history of HIT.
Avoid concomitant use with other anticoagulants unless carefully monitored.
Evaluate patients who develop thrombosis after heparin discontinuation for HIT or delayed complications.
Educate patients about signs of bleeding and importance of reporting unusual bruising or hemorrhage.

Warnings

Risk of serious hemorrhagic complications including intracranial, gastrointestinal, or surgical site bleeding.
Potential for life-threatening heparin-induced thrombocytopenia with thrombotic sequelae.
Discontinue drug promptly if bleeding occurs or coagulation tests are excessively prolonged.
Use extreme caution in patients with ulcerative gastrointestinal lesions or hemorrhagic blood dyscrasias.
Avoid use in patients with uncontrollable active bleeding except when managing disseminated intravascular coagulation.
Monitor for signs of adrenal hemorrhage; prompt corticosteroid therapy may be life-saving.
Heparin resistance may complicate dosing and anticoagulant effect assessment.
Fatal medication errors have been reported due to confusion between therapeutic and flush concentrations.
Patients with hypersensitivity to heparin or pork should not receive the drug except in life-threatening situations.
Avoid use of heparin lock flush solutions systemically to prevent overdose.
Use caution during neuraxial anesthesia or spinal puncture due to risk of spinal hematoma.
Pregnant women require preservative-free formulations to minimize fetal toxicity risk.
Nursing infants may be exposed to benzyl alcohol from maternal serum; caution advised.
Periodic hematologic monitoring including platelet counts and occult blood in stool recommended.
Report all medication errors or adverse events to regulatory authorities.

Contraindication

Uncontrollable active bleeding, unless due to disseminated intravascular coagulation.
Severe thrombocytopenia or known history of heparin-induced thrombocytopenia (HIT) with or without thrombosis.
Hypersensitivity to heparin or pork derivatives.
Inability to perform adequate laboratory monitoring while on full-dose therapy, except for low-dose prophylactic regimens.
Patients with documented heparin allergy except in life-threatening situations.
Do not use intramuscularly due to risk of hematoma.
Patients with severe bleeding disorders unrelated to disseminated intravascular coagulation.
Concomitant use with other anticoagulants without close monitoring leading to excessive anticoagulation.
Individuals with a history of severe bleeding complications due to anticoagulant therapy.
Known bleeding lesions such as active peptic ulcer disease or cerebral hemorrhage.
Epidural or spinal puncture patients at high risk of hemorrhagic complications.
Patients with significant hepatic impairment leading to coagulopathy and bleeding tendencies.
Patients with uncontrolled severe hypertension due to risk of hemorrhagic stroke.

Drug Interactions

Enhanced bleeding risk when combined with platelet-function inhibitors such as aspirin or NSAIDs.
Oral anticoagulants (e.g., warfarin) may prolong prothrombin time; careful monitoring required when transitioning.
Antithrombin III supplementation increases heparin anticoagulant effect; dose adjustment necessary.
Concurrent use with dextran may potentiate hemorrhagic complications; use cautiously.
Antihistamines and digitalis may partially antagonize heparin's anticoagulant effects.
Dipyridamole and hydroxychloroquine can increase bleeding risk with heparin.
Nitroglycerin may antagonize anticoagulant effect; monitor and adjust heparin dosage accordingly.
NSAIDs and phenylbutazone increase risk of bleeding during heparin therapy; co-administration should be cautious.
Tetracyclines may counteract anticoagulant effects; consider alternative antibiotics if possible.
Thrombolytic agents increase bleeding risk and require adjustment of heparin dose and coagulation monitoring.
Potential false elevation of liver enzymes (AST/ALT) during heparin therapy must be interpreted cautiously.
Pharmacodynamic interactions with other anticoagulants require close coagulation monitoring.
Heparin may interfere with certain coagulation assays; timing of blood draws relative to dosing is critical.
Heparin lock flushes should not be used systemically to avoid additive interactions or overdose.
No significant cytochrome P450-mediated pharmacokinetic interactions have been reported.

Preparations Of The Drug

Heparin Sodium Injection: Available in multiple concentrations including 1000, 5000, 10,000, and 20,000 units/mL for intravenous or subcutaneous administration.
Heparin Lock Flush Solutions: Formulations with 10 units/mL (available in various unit quantities like 10, 20, 30, 50, 100, 300 units) and 100 units/mL (ranging from 100 to 3000 units) for catheter patency.
Preservative-Free Heparin Sodium: Offered in solutions containing heparin diluted in 5% dextrose or sodium chloride solutions at concentrations such as 40 units/mL (20,000 units total), 50 units/mL (12,500 and 25,000 units), and 100 units/mL (10,000 and 25,000 units) for safe administration in neonates, pregnant, and nursing patients.
Heparin Sodium in Dextrose Injection: Various strengths for IV infusion including 2 units/mL (1000 or 2000 units), 50 units/mL (12,500 and 25,000 units), and 100 units/mL (25,000 units) to facilitate continuous infusion therapies.
Heparin Sodium in Sodium Chloride Injection: Provided in concentrations like 2 units/mL and 50–100 units/mL to accommodate different infusion protocols.
Heparin derived from porcine intestinal mucosa, ensuring purity and consistent activity per USP standards.
Formulations are packaged to allow flexibility in dosing for different clinical indications including bolus, continuous infusion, and maintenance flushes.
Available from multiple manufacturers, distributors, and repackagers under generic and brand names.
Labeling now requires clear indication of total units per container alongside units per milliliter to reduce medication errors.
Multiple-dose vials are available but unused portions should be discarded after single use when using single-dose vials.